Clinical trials: Endocrine System Diseases
Urologic Diseases, Hypospadias
Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel
This study aims to evaluate the utility of long-acting liposomal bupivacaine (Exparel®) in improving pain scores and reducing narcotic pain requirements in pediatric patients following minor urologic procedures.
- Conditions
- Urologic Diseases, Hypospadias, Undescended Testes, Chordee
- Trial name
- Baby ORIOLES (NCT04826484)
- Testing
- Exparel 133 miligrams per 10 milliliter injection, Bupivacaine Hydrochloride
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Johns Hopkins University
Type 1 Diabetes
Patient and Provider Glucose Reporting Preferences Ambulatory Glucose Profile (AGP)
International Diabetes Center (IDC) proposes a preference and usability study of glucose data acquisition and reporting, evaluating streamlined standardized cloud-based glucose reporting including work flow as well as patient and…
- Trial name
- NCT02074384
- Testing
- Continuous Glucose Monitor, Self Monitoring Blood Glucose, Clinician
- Where
- 7 sites in United States
- Volunteers
- 161 people
- Sponsor
- HealthPartners Institute
Diabetes, Type 2
Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus
B2611002 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 5 treatments for 3 months.
- Trial name
- NCT01336738
- Testing
- 150 mg PF-04991532, 450 mg PF-04991532, 750 mg PF-04991532
- Where
- 44 sites in United States, Canada and 5 more
- Volunteers
- 266 people
- Sponsor
- Pfizer
Cancer of Pancreas
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
Determine the overall response rate (ORR) of bemcentinib plus chemotherapy (nab-paclitaxel/gemcitabine) in patients with metastatic pancreatic adenocarcinoma.
- Trial name
- NCT03649321
- Testing
- Bemcentinib, Nab-paclitaxel, Gemcitabine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer, Ovarian Cancer
FPA150 in Patients With Advanced Solid Tumors
This is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or in combination with pembrolizumab an anti-PD1…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer, Advanced Solid Tumors
- Trial name
- FPA150-001 (NCT03514121)
- Testing
- FPA150, Pembrolizumab
- Where
- 18 sites in United States, South Korea
- Volunteers
- 95 people
- Sponsor
- Five Prime Therapeutics, Inc.
Type 2 Diabetes Mellitus
A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy
Study B1621018 will assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Dose Levels of Pf-04937319 in Japanese Subjects with Type 2 Diabetes Mellitus As Monotherapy
- Trial name
- NCT02292433
- Testing
- PF-04937319 high dose, PF-04937319 low dose
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Pfizer
Cardiovascular Diseases, Diabetes
Moderate Alcohol and Cardiovascular Health Trial
The Moderate Alcohol and Cardiovascular Health Trial (MACH15) is a multicenter, worldwide, randomized clinical trial of ~15 gm of alcohol daily versus abstention, using a balanced parallel design and single-blind assessment of…
- Trial name
- MACH15 (NCT03169530)
- Testing
- Alcohol
- Where
- 4 sites in United States, Netherlands and 1 more
- Volunteers
- 103 people
- Sponsor
- Beth Israel Deaconess Medical Center
Congenital Adrenal Hyperplasia
A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH
An investigation of the efficacy and safety of up to 70 weeks of treatment with Tildacerfont in subjects with classic CAH who have elevated biomarkers at baseline on their current GC regimen.
- Trial name
- NCT04457336
- Where
- 65 sites in United States, Australia and 18 more
- Volunteers
- 96 people
- Sponsor
- Spruce Biosciences
Diabetes, Foot Ulcer
Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers
After determining if subjects meet the criteria to be included in the study they will be randomly placed in either Group 1 or 2 and patient will be blinded from randomization group.
- Trial name
- NCT01108263
- Testing
- INTEGRA™ Flowable Matrix (Collagen)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Georgetown University
Advanced or Recurrent Solid Tumors, Breast Neoplasms
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
This is a single-arm, open-label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of talazoparib in patients with advanced tumors with DNA-repair pathway deficiencies.
- Conditions
- Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma
- Trial name
- NCT01286987
- Testing
- Talazoparib
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 113 people
- Sponsor
- Pfizer
Diabetes Mellitus, Impaired Fasting Glucose
Effect of Red Blood Cell Survival on a Commonly Used Diabetes Lab Test-HbA1c
Prevention of complications in veterans with diabetes depends heavily on assessment of blood glucose and HbA1c. The HbA1c is a blood test that measures the exposure of hemoglobin (Hb) to a person's average blood glucose over the…
- Conditions
- Diabetes Mellitus, Impaired Fasting Glucose, Prediabetes
- Trial name
- NCT01204216
- Testing
- re-infusion of biotin labeled cells, Diabetes education/diabetes medication adjustment
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Type II Diabetes Mellitus
The Effect of Linagliptin on Mitochondrial and Endothelial Function
Investigators propose to examine the effect of 12 weeks of Linagliptin, a diabetes drug, treatment on inflammation as well as vascular and mitochondrial function in diabetic patients.
- Trial name
- NCT01969084
- Testing
- Linagliptin, Microcirculation testing, Macrocirculation testing
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Beth Israel Deaconess Medical Center
Nasopharyngeal Carcinoma
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
The purpose of this randomized controlled Phase II study is to assess the efficacy of PDR001 versus investigator's choice of chemotherapy in patients with advanced nasopharyngeal carcinoma (NPC).
- Trial name
- NCT02605967
- Testing
- Spartalizumab, Investigator choice of chemotherapy
- Where
- 18 sites in United States, China and 5 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics
This study is designed to assess the effect of the different continuous s.c. infusion treatments on the human growth hormone (hGH) levels in untreated acromegalic patients in comparison to a standard dose of octreotide.
- Trial name
- NCT02217800
- Testing
- saline, DG3173, octreotide
- Volunteers
- 8 people
- Sponsor
- Aspireo Pharmaceuticals Limited
Pancreatic Cancer
Proton Therapy for Unresectable Cancer (CA) of Pancreas
The purpose of this study is to find out what effects, good and/or bad, proton radiation and chemotherapy has on you and your pancreatic cancer.
- Trial name
- PC01 (NCT00685763)
- Testing
- Proton radiation and chemotherapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Florida
Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
This phase II trial is studying how well gossypol acetic acid works in treating patients with recurrent, metastatic, or primary adrenocortical cancer that cannot be removed by surgery.
- Conditions
- Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma, Stage IV Adrenocortical Carcinoma
- Trial name
- NCT00848016
- Testing
- R-(-)-gossypol acetic acid
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
Surgical resection is the only potentially curative treatment for patients with pancreatic cancer. Patients with BRPC have tumors in close contact with the vasculature but not to the extent that resection is prohibited.
- Trial name
- NCT03099265
- Testing
- neoadjuvant mFOLFIRINOX, Stereotactic body radiotherapy (SBRT)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Yale University
Diabetes, Weight Loss
De Por Vida: A Diabetes Risk Reduction Intervention for Hispanic Women
This pragmatic randomized clinical trial will assess the efficacy, cost, and sustainability of a culturally tailored weight-loss program targeting obese Hispanic women with pre-diabetes or T2D.
- Conditions
- Diabetes, Weight Loss, PreDiabetes, Obesity
- Trial name
- NCT03113916
- Testing
- Behavioural Lifestyle Intervention
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Lung Cancer, Pancreatic Cancer
Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer
The purpose of this study is to characterize the safety and tolerability of AMG 706 plus panitumumab when administered with gemcitabine and cisplatin chemotherapy. This is a Phase 1b clinical study.
- Conditions
- Lung Cancer, Pancreatic Cancer, Esophageal Cancer
- Trial name
- NCT00101907
- Testing
- AMG 706, Panitumumab, Gemcitabine
- Volunteers
- 41 people
- Sponsor
- Amgen
Ovarian Cancer
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
This multi-institutional phase I/II clinical trial will test the tolerability and efficacy of the combination sorafenib and topotecan in patients with recurrent ovarian cancer, which is platinum-resistant (recurrence within 6…
- Trial name
- NCT00526799
- Testing
- Sorafenib, Topotecan
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Daniela Matei, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.